My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format

Send to:

Choose Destination

    Clin Infect Dis. 2002 Nov 1;35(9):e92-5. Epub 2002 Oct 9.

    Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity.

    Lacy MD, Maguire JD, Barcus MJ, Ling J, Bangs MJ, Gramzinski R, Basri H, Sismadi P, Miller GB, Chulay JD, Fryauff DJ, Hoffman SL, Baird JK.

    Parasitic Diseases Program, US Naval Medical Research Unit 2, Jakarta, Indonesia.

    Thirty-eight of 295 subjects participating in a randomized, double-blind, placebo-controlled trial of the efficacy of daily administration of atovaquone/proguanil for malaria prevention developed malaria at some time during the 20-week prophylaxis period. These subjects (3 atovaquone/proguanil recipients and 35 placebo recipients) were treated with 4 tablets of atovaquone/proguanil per day for 3 days. Atovaquone/proguanil provided safe, well-tolerated, and effective therapy for uncomplicated malaria in nonimmune Indonesians.

    PMID: 12384852 [PubMed - indexed for MEDLINE]

    Publication Types, MeSH Terms, Substances

    Publication Types:

    MeSH Terms:

    Substances:

    LinkOut - more resources

    Full Text Sources:

    Molecular Biology Databases:

    Libraries:

    Supplemental Content

    Click here to read Click here to read Click here to read

    Related articles

    Cited by 3 PubMed Central articles

    Patient drug information

    • Atovaquone (Mepron®)

      Atovaquone is used to treat Pneumocystis carinii pneumonia (PCP).

    • Source: AHFS Consumer Medication Information

    All links from this record

    • Related Articles

      Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.

    • Compound (MeSH Keyword)

      PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

    • Substance (MeSH Keyword)

      PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

    • Cited in PMC

      Full-text articles in the PubMed Central Database that cite the current articles.

    • Cited in Books

      NCBI Bookshelf books that cite the current articles.

    Recent activity